|
[1]
|
Rye, K.A. and Barter, P.J. (2014) Cardioprotective Functions of HDLs. Journal of Lipid Research, 55, 168-179. [Google Scholar] [CrossRef]
|
|
[2]
|
Rosenson, R.S., Brewer, H.B., Ansell, B., et al. (2013) Translation of High-Density Lipoprotein Function into Clinical Practice: Current Prospects and Future Challenges. Circulation, 128, 1256-1267. [Google Scholar] [CrossRef]
|
|
[3]
|
Navab, M., Reddy, S.T., Van Lenten, B.J. and Fogelman, A.M. (2011) HDL and Cardiovascular Disease: Atherogenic and Atheroprotective Mechanisms. Nature Re-views Cardiology, 8, 222-232. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Favari, E., Thomas, M.J. and Sor-ci-Thomas, M.G. (2018) High-Density Lipoprotein Functionality as a New Pharmacological Target on Cardiovascular Disease: Unifying Mechanism That Explains High-Density Lipoprotein Protection toward the Progression of Athero-sclerosis. Journal of Cardiovascular Pharmacology, 71, 325-331. [Google Scholar] [CrossRef]
|
|
[5]
|
Schwertani, A., Choi, H.Y. and Genest, J. (2018) HDLs and the Pathogenesis of Atherosclerosis. Current Opinion in Cardiology, 33, 311-316. [Google Scholar] [CrossRef]
|
|
[6]
|
Rader, D.J., Hoeg, J.M. and Brewer, H.B. (1994) Quantita-tion of Plasma Apolipoproteins in the Primary and Secondary Prevention of Coronary Artery Disease. Annals of Internal Medicine, 120, 1012-1025. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Sniderman, A.D. and Faraj, M. (2007) Apolipoprotein B, Apolipoprotein A-I, Insulin Resistance and the Metabolic Syndrome. Current Opinion in Lipidology, 18, 633-637. [Google Scholar] [CrossRef]
|
|
[8]
|
Chou, Y.C., You, S.L., Bai, C.H., Liao, Y.C., Wei, C.Y., Sun, C.A., et al. (2020) Utility of Apolipoprotein Measurements in Predicting Incident Type 2 Diabetes: A Chinese Cohort Study. Journal of the Formosan Medical Association, 119, 51-58. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Wu, X., Yu, Z., Su, W., Isquith, D.A., Neradilek, M.B., Lu, N., et al. (2017) Low Levels of ApoA1 Improve Risk Prediction of Type 2 Diabetes Mellitus. Journal of Clinical Lipidology, 11, 362-368. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Hwang, Y.C., Ahn, H.Y., Park, S.W. and Park, C.Y. (2014) Asso-ciation of HDL-C and Apolipoprotein A-I with the Risk of Type 2 Diabetes in Subjects with Impaired Fasting Glucose. European Journal of Endocrinology, 171, 137-142. [Google Scholar] [CrossRef]
|
|
[11]
|
Hashemi, M., Saadat, M., Behjati, M. and Kelishadi, R. (2012) Compar-ison of Serum Apolipoprotein Levels of Diabetic Children and Healthy Children with or without Diabetic Parents. Cho-lesterol, 2012, Article ID: 490381. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Zheng, S., Han, T., Xu, H., Zhou, H., Ren, X., Wu, P., et al. (2017) Associations of Apolipoprotein B/Apolipoprotein A-I Ratio with Pre-Diabetes and Diabetes Risks: A Cross-Sectional Study in Chinese Adults. BMJ Open, 7, Article ID: 014038. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Hwang, Y.C., Ahn, H.Y., Kim, W.J., Park, C.Y. and Park, S.W. (2012) Increased apoB/A-I Ratio Independently Associated with Type 2 Diabetes Mellitus: Cross-Sectional Study in a Korean Population. Diabetic Medicine, 29, 1165-1170. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Onat, A., Komurcu-Bayrak, E., Can, G., Kucukdurmaz, Z., Hergenc, G., Erginel Unaltuna, N., et al. (2010) Apolipoprotein A-I Positively Associated with Diabetes in Women In-dependently of Apolipoprotein E Genotype and Apolipoprotein B Levels. Nutrition, 26, 975-980. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Mellor, D.D., Georgousopoulou, E.N., D’Cunha, N.M., Naumovski, N., Chrysohoou, C., Tousoulis, D., et al. (2020) Association between Lipids and Apolipoproteins on Type 2 Diabetes Risk, Moderating Effects of Gender and Polymorphisms, the ATTICA Study. Nutrition, Metabolism and Cardiovascu-lar Diseases, 30, 788-795. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Ndumele, C.E., Matsushita, K., Astor, B., Virani, S.S., Mora, S., Williams, K.E., et al. (2014) Apolipoproteins Do Not Add Prognostic Information beyond Lipoprotein Cholesterol Measures among Individuals with Obesity and Insulin Resistance Syndromes: The ARIC Study. European Journal of Preventive Cardiology, 21, 866-875. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Aryan, Z., Afarideh, M., Ghajar, A., Esteghamati, S., Esteghamati, A. and Nakhjavani, M. (2017) Conflicting Interactions of Apolipoprotein A and High Density Lipoprotein Cholesterol with Microvascular Complications of Type 2 Diabetes. Diabetes Research and Clinical Practice, 133, 131-141. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Moosaie, F., Firouzabadi, F.D., Abouhamzeh, K., Esteghamati, S., et al. (2020) Lp(a) and Apo-Lipoproteins as Predictors for Micro- and Macrovascular Complications of Diabetes: A Case-Cohort Study. Nutrition, Metabolism & Cardiovascular Diseases, 30, 1723-1731. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Moore, R.E., Kawashiri, M.A., Kitajima, K., Secreto, A., Millar, J.S., Pratico, D. and Rader, D.J. (2003) Apolipoprotein A-I Deficiency Results in Markedly Increased Atherosclerosis in Mice Lacking the LDL Receptor. Arteriosclerosis, Thrombosis, and Vascular Biology, 23, 1914-1920. [Google Scholar] [CrossRef]
|
|
[20]
|
Benoit, P.P., Emmanuel, F.P., Caillaud, J.M.M.D., Bassinet, L., Castro, G.P., Gallix, P.D.V.M., Fruchart, J.C.P., Branellec, D.P., Denefle, P.P. and Duverger, N.P. (1999) Somatic Gene Transfer of Human apoA-I Inhibits Atherosclerosis Progression in Mouse Models. Circulation, 99, 105-110. [Google Scholar] [CrossRef]
|
|
[21]
|
Schmidt, A.F., Joshi, R., Gordillo-Marañón, M., Drenos, F., Charoen, P., et al. (2023) Biomedical Consequences of Elevated Cholesterol Containing Lipoproteins and Apolipo-proteins on Cardiovascular and Non-Cardiovascular Outcomes. Communications Medicine, 3, 9. [Google Scholar] [CrossRef]
|
|
[22]
|
Tang, S., et al. (2019) Apolipoprotein A-I Enhances insu-lin-Dependent and Insulin-Independent Glucose Uptake by Skeletal Muscle. Scientific Reports, 9, Article No. 1350. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Wu, B.J., et al. (2019) Apolipoprotein A-I Protects against Pregnancy-Induced Insulin Resistance in Rats. Arteriosclerosis, Thrombosis, and Vascular Biology, 39, 1160-1171. [Google Scholar] [CrossRef]
|
|
[24]
|
Zhang, X., et al. (2015) Genetic Polymorphism of APOB Is Associated with Diabetes Mellitus in Sickle Cell Disease. Human Genetics, 134, 895-904. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Saleheen, D., Scott, R., Javad, S., Zhao, W., Rodrigues, A., Pi-cataggi, A., Lukmanova, D., Mucksavage, M.L., Luben, R., Billheimer, J., et al. (2015) Association of HDL Cholesterol Efflux Capacity with Incident Coronary Heart Disease Events: A Prospective Case-Control Study. The Lancet Diabetes & Endocrinology, 3, 507-513. [Google Scholar] [CrossRef]
|
|
[26]
|
Tsun, J.G., Shiu, S.W., Wong, Y., Yung, S., Chan, T.M. and Tan, K.C. (2013) Impact of Serum Amyloid A on Cellular Cholesterol Efflux to Serum in Type 2 Diabetes Mellitus. Ath-erosclerosis, 231, 405-410. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Fritzen, A.M., Domingo-Espín, J., Lundsgaard, A.M., Kleinert, M., Israelsen, I., Carl, C.S., et al. (2020) ApoA-1 Improves Glucose Tolerance by Increasing Glucose Uptake into Heart and Skeletal Muscle Independently of AMPKα2. Molecular Metabolism, 35, Article ID: 100949. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Skogsberg, J., Dicker, A., Rydén, M., Aström, G., Nilsson, R., Bhuiyan, H., et al. (2008) ApoB100-LDL Acts as a Metabolic Signal from Liver to Peripheral Fat Causing Inhibition of Lipolysis in Adipocytes. PLOS ONE, 3, e3771. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Watts, G.F., Ooi, E.M. and Chan, D.C. (2009) Therapeutic Regulation of apoB100 Metabolism in Insulin Resistance in Vivo. Pharmacology & Therapeutics, 123, 281-291. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Sierra-Johnson, J., Romero-Corral, A., Somers, V.K., et al. (2007) ApoB/apoA-I Ratio: An Independent Predictor of Insulin Resistance in US Non-Diabetic Subjects. European Heart Journal, 28, 2637-2643. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Meriwether, D., Sulaiman, D., Volpe, C., Dorfman, A., Grijalva, V., Dorreh, N., et al. (2019) Apolipoprotein A-I Mimetics Mitigate Intestinal Inflammation in COX2-Dependent Inflamma-tory Bowel Disease Model. Journal of Clinical Investigation, 129, 3670-3685. [Google Scholar] [CrossRef]
|
|
[32]
|
Gabás-Rivera, C., Barranquero, C., Martínez-Beamonte, R., Navarro, M.A., Surra, J.C. and Osada, J. (2014) Dietary Squalene Increases High Density Lipoprotein-Cholesterol and Paraoxonase 1 and Decreases Oxidative Stress in Mice. PLOS ONE, 9, e104224. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Lee, J.Y., Kang, M.J., Choi, J.Y., Park, J.S., Park, J.K., Lee, E.Y., et al. (2018) Apolipoprotein B Binds to Enolase-1 and Aggravates Inflammation in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 77, 1480-1489. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Alvarez, C.A., Lingvay, I., Vuylsteke, V., Koffarnus, R.L. and McGuire, D.K. (2015) Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglyce-mic Medications. Clinical Pharmacology & Therapeutics, 98, 145-161. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Hoang, A., Murphy, A.J., Coughlan, M.T., Thomas, M.C., Forbes, J.M., O’Brien, R., et al. (2007) Advanced Glycation of Apolipoprotein A-I Impairs Its Anti-Atherogenic Properties. Diabetologia, 50, 1770-1779. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Nobecourt, E., Davies, M.J., Brown, B.E., Curtiss, L.K., Bonnet, D.J., Charlton, F., et al. (2007) The Impact of Glycation on Apolipoprotein A-I Structure and Its Ability to Activate Lec-ithin: Cholesterol Acyltransferase. Diabetologia, 50, 643-653. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Nobecourt, E., Tabet, F., Lambert, G., Puranik, R., Bao, S., Yan, L., et al. (2010) Nonenzymatic Glycation Impairs the Antiinflammatory Properties of Apolipoprotein A-I. Arteriosclero-sis, Thrombosis, and Vascular Biology, 30, 766-772. [Google Scholar] [CrossRef]
|
|
[38]
|
Liu, D.H., Ji, L., Zhao, M.M., Wang, Y., Guo, Y.S., Li, L., Zhang, D.M., et al. (2018) Lysine Glycation of Apolipoprotein A-I Impairs Its Antiinflammatory Function in Type 2 Diabetes Mellitus. Journal of Molecular and Cellular Cardiology, 122, 47-57.
|
|
[39]
|
Panagotopulos, S.E., Witting, S.R., Horace, E.M., Hui, D.Y., Maiorano, J.N. and Davidson, W.S. (2002) The Role of Apolipoprotein A-I Helix 10 in Apolipoprotein-Mediated Cholesterol Efflux via the ATP-Binding Cassette Transporter ABCA1. Journal of Biological Chemistry, 277, 39477-39484. [Google Scholar] [CrossRef]
|
|
[40]
|
Brown, B.E., Nobecourt, E., Zeng, J., Jenkins, A.J., Rye, K.A. and Davies, M.J. (2013) Apolipoprotein A-I Glycation by Glucose and Reactive Aldehydes Al-ters Phospholipid Affinity but Not Cholesterol Export from Lipid-Laden Macrophages. PLOS ONE, 8, e65430. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
von Zychlinski, A., Kleffmann, T., Williams, M.J. and McCor-mick, S.P. (2011) Proteomics of Lipoprotein(a) Identifies a Protein Complement Associated with Response to Wounding. Journal of Proteomics, 74, 2881-2891. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Nordestgaard, B.G., Chapman, M.J., Ray, K., et al. (2010) Lip-oprotein(a) as a Cardiovascular Risk Factor: Current Status. European Heart Journal, 31, 2844-2853. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Helgadottir, A., Gretarsdottir, S., Thorleifsson, G., et al. (2012) Apolipoprotein(a) Genetic Sequence Variants Associated with Systemic Atherosclerosis and Coronary Atherosclerotic Burden but Not with Venous Thromboembolism. Journal of the American College of Cardiology, 60, 722-729. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Kral, B.G., Kalyani, R.R., Yanek, L.R., et al. (2016) Relation of Plasma Lipoprotein(a) to Subclinical Coronary Plaque Volumes, Three-Vessel and Left Main Coronary Disease, and Se-vere Coronary Stenoses in Apparently Healthy African-Americans with a Family History of Early-Onset Coronary Ar-tery Disease. American Journal of Cardiology, 118, 656-661. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Clarke, R., Peden, J.F., Hopewell, J.C., et al. (2009) Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease. The New England Journal of Medicine, 361, 2518-2528. [Google Scholar] [CrossRef]
|
|
[46]
|
Kamstrup, P.R., Tybjærg-Hansen, A. and Nordestgaard, B.G. (2014) Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population. Journal of the Ameri-can College of Cardiology, 63, 470-477. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Thanassoulis, G., Campbell, C.Y., Owens, D.S., et al. (2013) Ge-netic Associations with Valvular Calcification and Aortic Stenosis. The New England Journal of Medicine, 368, 503-512. [Google Scholar] [CrossRef]
|
|
[48]
|
Thanassoulis, G. (2016) Lipoprotein(a) in Calcific Aortic Valve Disease: From Genomics to Novel Drug Target for Aortic Stenosis. Journal of Lipid Research, 57, 917-924. [Google Scholar] [CrossRef]
|
|
[49]
|
Kamstrup, P.R. (2010) Lipoprotein(a) and Ischemic Heart Disease—A Causal Association? A Review. Atherosclerosis, 211, 15-23. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Schmidt, K., Noureen, A., Kronenberg, F. and Utermann, G. (2016) Structure, Function, and Genetics of Lipoprotein(a). Journal of Lipid Research, 57, 1339-1359. [Google Scholar] [CrossRef]
|
|
[51]
|
Bao, X., Borne, Y., Muhammad, I.F., et al. (2019) Growth Differentiation Factor 15 Is Positively Associated with Incidence of Diabetes Mellitus: The Malmo Diet and Cancer-Cardiovascular Co-hort. Diabetologia, 62, 78-86. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Woodward, L., Akoumianakis, I. and Antoniades, C. (2017) Un-ravelling the Adiponectin Paradox: Novel Roles of Adiponectin in the Regulation of Cardiovascular Disease. British Journal of Pharmacology, 174, 4007-4020. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Li, S., Shin, H.J., Ding, E.L. and van Dam, R.M. (2009) Adiponectin Lev-els and Risk of Type 2 Diabetes: A Systematic Review and Meta-Analysis. JAMA, 302, 179-188. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Klose, R., Adam, M.G., Weis, E.-M., et al. (2018) Inactivation of the Serine Protease HTRA1 Inhibits Tumor Growth by Deregulating Angiogenesis. Oncogene, 37, 4260-4272. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Skorko-Glonek, J., Zurawa-Janicka, D., Koper, T., et al. (2013) HtrA Protease Family as Therapeutic Targets. Current Pharmaceutical Design, 19, 977-1009. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
van Nieuwenhoven, F.A., Munts, C., Op’t Veld, R.C., et al. (2017) Cartilage Intermediate Layer Protein 1 (CILP1): A Novel Mediator of Cardiac Extracellular Matrix Remodelling. Scientific Reports, 7, Article No. 16042. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Wu, T., Zhang, Q., Wu, S., et al. (2019) CILP-2 Is a Novel Se-creted Protein and Associated with Insulin Resistance. Journal of Molecular Cell Biology, 11, 1083-1094. [Google Scholar] [CrossRef] [PubMed]
|